Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targets
Open Access
- 1 January 2013
- journal article
- review article
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 4 (1), 72
- https://doi.org/10.4103/2152-7806.112822
Abstract
Chordomas of the skull base are rare locally aggressive neoplasms with a predilection for encapsulating critical neurovascular structures, bony destruction and irregular growth patterns, and from which patients succumb to recurrence and treatment failures. A review of the medical literature is performed, using standard search engines and identifying articles related to skull base chordomas, surgery, radiation therapy, chemotherapy, molecular genetics, and prospective trials. A synthesis of the literature is presented, including sections on pathology, treatment, molecular genetics, challenges, and future directions. Beyond an understanding of the current treatment paradigms for skull base chordomas, the reader gains insight into the collaborative approach applied to orphan diseases, of which chordomas is a prime exemplar.This publication has 91 references indexed in Scilit:
- Aldehyde Dehydrogenase 1, a Potential Marker for Cancer Stem Cells in Human SarcomaPLOS ONE, 2012
- Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature reviewBMC Cancer, 2011
- Recurrent Chromosomal Copy Number Alterations in Sporadic ChordomasPLOS ONE, 2011
- Molecular Characterization of Putative Chordoma Cell LinesSarcoma, 2010
- Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-StudyBMC Cancer, 2010
- T (brachyury) gene duplication confers major susceptibility to familial chordomaNature Genetics, 2009
- Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathwayBritish Journal of Cancer, 2009
- Chordoma and chondrosarcoma gene profile: implications for immunotherapyCancer Immunology, Immunotherapy, 2008
- A Dual Phosphoinositide-3-Kinase α/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN-Mutant GliomaCancer Research, 2007
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006